<DOC>
	<DOCNO>NCT01985334</DOCNO>
	<brief_summary>The main goal study evaluate efficacy safety glycopyrronium bromide indacaterol maleate glycopyrronium bromide fix dose combination ( FDC ) patient moderate COPD switch current COPD therapy . This study aim provide data non-exacerbating , still symptomatic patient moderate COPD switch current COPD treatment glycopyrronium bromide indacaterol maleate glycopyrronium bromide FDC maintain improve symptom . Another purpose study increase awareness usage validate COPD symptom tool dyspnea questionnaire order facilitate clinical assessment improve early diagnosis symptomatic patient .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Glycopyrronium Indacaterol Maleate Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms Health Status Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen</brief_title>
	<detailed_description>The treatment epoch last 12 week . The total duration study patient 12 week ( randomization ) plus 30 day safety follow-up . The study three phase : screening phase ( =wash-out period , require ) , treatment phase safety follow-up phase . Eligible patient randomize either receive glycopyrronium indacaterol maleate glycopyrronium bromide fix dose combination remain baseline therapy , allocation ratio 3:1 cluster ( Groups A , B , C , D ) , base COPD symptom baseline treatment : Group A : Patients treat SABA ( Short-acting β2-adrenergic agonist ) and/or SAMA ( Short-acting muscarinic antagonist ) monotherapy free fix dose combination ( FDC ) assign glycopyrronium remain baseline therapy ( 3:1 ) Group B : Patients treat LABA ( Long-acting β2-adrenergic agonist ) LAMA ( Long-acting muscarinic antagonist ) monotherapy mMRC score =1 point assign glycopyrronium remain baseline therapy ( 3:1 ) Group C : Patients treat LABA ICS ( Inhaled corticosteroid ) free FDC assign indacaterol maleate glycopyrronium bromide fix dose combination remain baseline therapy ( 3:1 ) Group D : Patients treat LABA LAMA monotherapy mMRC score &gt; 1 point assign indacaterol maleate glycopyrronium bromide fix dose combination remain baseline therapy ( 3:1 )</detailed_description>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Muscarinic Antagonists</mesh_term>
	<criteria>Male female adult age ≥ 40 year Patients moderate COPD accord GOLD criterion 2013 Current exsmokers smoke history least 10 pack year Patients airflow limitation indicate postbronchodilator FEV1 ≥50 % &lt; 80 % predict normal value postbronchodilator FEV1/FVC &lt; 0.7 Visit 2 . Post bronchodilator refers within 1015 min inhalation 400 μg ( 4x100 μg ) salbutamol Patients , Visit 1 , least 3 month stable dose one follow COPD baseline treatment : *Any SABA monotherapy ( , limit , salbutamol ) *Any SAMA monotherapy ( , limit , ipratropium ) *Any SABA SAMA free FDC ( , limit , salbutamol/ipratropium ) *Any LABA monotherapy ( , limit , formoterol , salmeterol , indacaterol ) *Any LAMA monotherapy ( , limit , tiotropium , aclidinium ) except glycopyrronium bromide ( NVA237 ) *Any LABA ICS free ( ICS , limit , beclomethasone , fluticasone ) FDC ( , limit , salmeterol/fluticasone , formoterol/budesonide ) . Patients mMRC score ≥1 Visit 1 . Patients condition contraindicate treatment , history reactions/ hypersensitivity follow inhaled drug drug similar chemical class component thereof : Anticholinergic agent , Long shortacting 2adrenergic agonist , Sympathomimetic amine , Lactose excipients trial medication . Patients narrowangle glaucoma urinary retention , severe renal impairment ( history estimate glomerular filtration rate 30 ml/min/1.73 m2 within 12 month prior visit 1 ) , include endstage renal disease require dialysis . Patients active/ clinical history asthma.If Investigator find clear compel evidence patient misdiagnosed asthma past , burden proof Investigator properly document previous misdiagnosis . This documentation must include rationale change diagnosis include reference differential diagnosis support decision . Patients history malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis . Patients postbronchodilator FEV1 decrease 10 % compare prebronchodilator FEV1 result Visit 2 ( see Appendix 5 detail ) . A documented history &gt; 1 COPD exacerbation require treatment systemic corticosteroid antibiotic and/or hospitalization previous 12 month . Patients NOT COPD exacerbation previous 12 month develop COPD exacerbation screening ( Visit 1 ) ( Visit 2 ) eligible permit rescreened minimum 6 week resolution COPD exacerbation . ( Patients suffer exacerbation Visit 1 Visit 2 rescreened case first one previous 12 month . In case COPD exacerbation lead alteration patient COPD treatment , patient rescreened 3 month stable COPD treatment require described Inclusion Criterion 6 ) . Patients , judgment investigator , clinically relevant laboratory abnormality clinically significant condition ( limited ) : *Unstable ischemic heart disease , leave ventricular failure ( NYHA Class III &amp; IV ) , history myocardial infarction , arrhythmia ( exclude chronic stable atrial fibrillation ) . Patients event consider clinically significant investigator may consider inclusion study . *Uncontrolled hypoor hyperthyroidism , hypokalaemia hyperadrenergic state . *Any condition might compromise patient safety compliance , interfere evaluation , preclude completion study History rest QTc ( Fridericia prefer , Bazett acceptable ) &gt; 450 msec ( male ) &gt; 460 msec ( female ) within five year Visit 1 . Patients treat glycopyrronium bromide ( NVA237 ) visit 1 allow include trialPatients nonselective betablockers . Those patient may enter study nonselective betablocker withdrawal 7day washout period . Patients receive prohibit COPDrelated medication specify Table 52 Prohibited COPD related medication must undergo require washout period prior Visit 2 . Patients , opinion investigator know unreliable noncompliant . Patients body mass index ( BMI ) 40 kg/m2 . Use investigational drug within 5 halflives enrollment within 30 day , whichever longer . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test . Women childbearing potential , defined woman physiologically capable become pregnant , unless use effective method contraception dose study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Moderate COPD , glycopyrronium bromide , indacaterol maleate glycopyrronium bromide FDC , NVA237 , QVA149</keyword>
</DOC>